IL6 and osteosarcoma: Furthermore, we determined that the anti-osteosarcoma activity of diosmetin was possibly attributed to suppressed activation of STAT3/c-Myc signaling pathway as it dose-dependently inhibited STAT3 phosphorylation and reduced c-Myc expression as well as inhibited STAT3 dimerization while its anti-proliferation effect was impeded by IL-6 by driving the activation of STAT3/c-Myc pathway (Fig. 7).